Verquvo Drug Quantity Management Policy
Defines quantity limits, one-time override rules, and approval durations for Verquvo (vericiguat) 2.5 mg, 5 mg, and 10 mg tablets for Cigna-administered health benefit plans. Applies at point-of-sale; if quantity management rule not met, coverage determined by criteria and approvals are time-limited.
Policy Statement was updated to clarify that 'one-time' overrides are provided for 30 days in duration.
Verquvo 2.5 mg and 5 mg tablets: Override criteria updated to approve 60 tablets at retail or 180 tablets at home delivery (previously 60 tablets at retail or home delivery).
Policy updated to reflect existing quantity limits when product obtained via home delivery.
Annual revisions with no criteria changes noted in prior years (04/06/2023, 04/22/2024).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.